Study of DAXDILIMAB for the Treatment of Moderate-to-Severe Alopecia Areata

Summary

The purpose of this study is to assess the preliminary efficacy, safety, tolerability, PK, and PD of Daxdilimab in participants with moderate to severe AA, with ≥50% and ≤95% total scalp hair loss as defined by the SALT score at Screening and Day 1.

Timeline

Start

2022-04-27

Primary completion

2023-08-07

Completion

2024-01-26

Drugs

Indications